Keyphrases
Temozolomide
100%
O6-methylguanine-DNA Methyltransferase
100%
Uterine Leiomyosarcoma
100%
Tumor
33%
Complete Response
33%
Methylguanine Methyltransferase
33%
Progression-free Interval
33%
Confidence Interval
16%
Pathologic
16%
Response Rate
16%
Immunohistochemistry
16%
Clinical Outcomes
16%
Clinical Benefit
16%
Clinical Response
16%
Stable Disease
16%
Partial Response
16%
Pathologist
16%
Leiomyosarcoma
16%
Dose Adjustment
16%
Progressive Disease
16%
Dose-limiting Toxicity
16%
Patient-derived
16%
Patient with Tumor
16%
Medicine and Dentistry
Leiomyosarcoma
100%
Temozolomide
100%
Methylated DNA Protein Cysteine Methyltransferase
100%
Neoplasm
50%
DNA Methyltransferase
50%
6 O Methylguanine
50%
Disease
33%
Progression Free Survival
33%
Immunohistochemistry
16%
Pathologist
16%
Chemotherapy
16%
Progressive Disease
16%
Pharmacology, Toxicology and Pharmaceutical Science
Temozolomide
100%
Methylated DNA Protein Cysteine Methyltransferase
100%
Leiomyosarcoma
100%
Neoplasm
50%
Disease
50%
DNA Methyltransferase
50%
6 O Methylguanine
50%
Progression Free Survival
33%